Study Summary
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.
Want to learn more about this trial?
Request More InfoInterventions
T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)BIOLOGICAL
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Seattle Children's Hospital | Seattle | Washington | United States |